Biodegradable Microparticles for Sustained NMDA Antagonist Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NMDA antagonist treatments, such as ketamine, for neuropsychiatric disorders like treatment-resistant anxiety and PTSD, result in undesirable side effects like dissociative symptoms and blood pressure increases due to short-acting formulations, necessitating the development of long-acting alternatives.
Innovation Solution
Development of pharmaceutical compositions containing NMDA antagonists encapsulated in biodegradable microparticles, specifically using polylactides and polyglycolides polymers, which release the active agent over 7 days to 90 days, reducing side effects and improving treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If short-acting NMDA antagonist formulations are used, then rapid therapeutic effect is achieved, but dissociative symptoms and cardiovascular side effects occur
Solution Approach 1:
The patent applies dynamics by transitioning from static rapid-release formulations to dynamic sustained-release formulations that modulate drug release over time. The microparticle system dynamically controls the release rate of NMDA antagonists, maintaining therapeutic plasma concentrations while avoiding peak-related side effects. This is achieved through biodegradable polymer matrices that gradually release the active agent over days to weeks.
Solution Approach 2:
The patent changes the temporal parameter of drug delivery from immediate release to sustained release over extended periods. By altering the release kinetics parameter through microparticle encapsulation, the formulation maintains plasma concentrations within the therapeutic window without the sharp peaks that cause dissociative symptoms and cardiovascular effects.
2Reliability
If repeated frequent injections are administered to maintain therapeutic levels, then continuous treatment effect is achieved, but treatment complexity and patient burden increase
Solution Approach 1:
The patent implements continuity of useful action by designing sustained-release microparticle formulations that maintain therapeutic plasma concentrations of NMDA antagonists over extended periods (days to weeks). This continuous release profile eliminates the need for frequent repeated injections, providing reliable continuous treatment effect while simplifying administration to a single or minimal number of injections.
3Reliability
If high doses of NMDA antagonists are administered to ensure therapeutic coverage, then treatment efficacy is improved, but side effects intensify
Solution Approach 1:
The patent changes the temporal distribution parameter of drug delivery, transforming bolus high-dose administration into sustained lower-dose release over time. The microparticle formulations release NMDA antagonists gradually, maintaining plasma concentrations within the therapeutic window without exceeding thresholds that trigger dissociative symptoms and cardiovascular side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained release of NMDA antagonists maintains therapeutic plasma concentrations for extended periods, reducing side effects and enhancing treatment outcomes for neuropsychiatric disorders.
Implementation Method 1
the microparticles may be composed of a biodegradable polymer such as, for example, polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolide) (PLGA) polymers
Data Source
AI summary
Sustained release formulations of NMDA antagonists containing encapsulated NMDA antagonist are described herein.